Stock market correction sends biopharma back to the start of 2021
Covid-19 vaccine developers stand out as global drug stocks tread water in the first quarter.
One victory for biopharma over the coronavirus in 2020
A rollercoaster year for biopharma ended with investors firmly deciding that the pandemic was an opportunity, not a threat.
Upcoming events – Avadel takes on Jazz and Axovant awaits early results
Data will soon show whether Avadel’s FT218 is more convenient than Jazz’s Xyrem, while Axovant will be looking for a dose response with its Parkinson’s gene therapy.
Plenty of choice remains for buyers of gene therapy
Despite the recent flurry of gene therapy deals there is still a fairly extensive list of affordable companies out there.
Cannabis, M&A and data spur strong gains among small and midcaps
The usual story of positive data and clinical failure influencing company stock performance was given added interest in the second quarter with price fixing allegations…
Roche buy-in is another vote of confidence in gene therapy
The Swiss group picks up Spark Therapeutics for $4.8bn, marking the biggest gene therapy buyout since Novartis’s $8.7bn move on Avexis.
Neurocrine voyages into gene therapy
A collaboration over four gene therapy programmes substantially beefs up Neurocrine’s pipeline, while Voyager Therapeutics gets a much-needed infusion of credibility.
